Skip to main content
Quest Diagnostics

Phenotype Frequencies for Psychiatric Versus Non-Psychiatric Pharmacogenomic Test Results From a National Laboratory

American Psychiatric Association, APA 2023

San Francisco, CA, May 20-24, 2023

Poster presentation: Phenotype frequencies for psychiatric versus non-psychiatric pharmacogenomic test results from a national laboratory

Authors: Lorenz RA, O’Brien K, Mahon L

Specialties: Genetics, Neurology, Prescription Drug Monitoring, Toxicology

Related content

Publication
Clinical and Economic Outcomes of a Pharmacogenomics-Enriched Comprehensive Medication Management Program in a Self-Insured Employee Population
Publication
Early insights from a pharmacogenomic-enriched comprehensive medication management program implementation in an adult employee population
On-Demand Webinar
Current state of Pharmacogenomics and its future
Audio Podcast
Pharmacogenomics in Mental Health and Addiction
Publication
Role of Pharmacogenomics in Comprehensive Medication Management: Considerations for Employers

Our company

Quest® is the brand name used for services offered by Quest Diagnostics Incorporated and its affiliated companies. Quest Diagnostics Incorporated and certain affiliates are CLIA-certified laboratories that provide HIPAA-covered services.  Other affiliates operated under the Quest® brand, such as Quest Consumer Inc., do not provide HIPAA-covered services. 

 

Quest®, Quest Diagnostics®, any associated logos, and all associated Quest Diagnostics registered or unregistered trademarks are the property of Quest Diagnostics. All third-party marks—® and ™—are the property of their respective owners. © 2025 Quest Diagnostics Incorporated. All rights reserved. Image content features models and is intended for illustrative purposes only.